GHRP-6

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, developmental code SKF-110679) is a synthetic hexapeptide and the prototypical growth hormone-releasing peptide from which the entire GHRP class evolved. It was discovered through systematic modification of met-enkephalin analogues — a line of medicinal chemistry pioneered by Cyril Bowers in the 1970s–80s that inadvertently identified potent GH-releasing activity in certain enkephalin-derived sequences. This serendipitous discovery opened the field of synthetic growth hormone secretagogues and ultimately led to the identification of ghrelin as the endogenous GHS-R1a ligand in 1999.

The mechanism is dual-action at the pituitary level: GHRP-6 activates GHS-R1a (the ghrelin receptor) → Gαq/11 → phospholipase C → IP3 → calcium mobilization → GH vesicle exocytosis, while simultaneously suppressing somatostatin tone to reduce the inhibitory brake on GH release. The combination of direct stimulation plus disinhibition produces robust, predictable GH pulses. The resulting serum GH spike peaks at 30–45 minutes post-administration and returns to baseline within approximately 2 hours.

What distinguishes GHRP-6 from later GHRPs (GHRP-2, Ipamorelin, Hexarelin) is its pronounced appetite-stimulating effect, mediated through GHS-R1a activation in hypothalamic arcuate nucleus NPY/AgRP neurons — the same orexigenic circuit activated by endogenous ghrelin. This makes GHRP-6 a dual-purpose research tool: a GH secretagogue for somatotropic axis studies and a ghrelin-mimetic for appetite and feeding-behavior research. At higher doses, GHRP-6 also produces measurable cortisol and prolactin elevation — effects that are substantially reduced in later, more selective GHRPs.

GHRP-6 was developed by Bowers and colleagues and later licensed to SmithKline Beecham (SKF-110679). It was the first GHRP to demonstrate robust, dose-dependent GH release in human subjects, proving that synthetic peptides could stimulate the somatotropic axis through a mechanism independent of GHRH. This discovery had profound implications: it demonstrated the existence of a second, non-GHRH pathway for GH regulation — a pathway that would later be explained by the 1999 discovery of ghrelin as the endogenous ligand for the GHS-R1a receptor.

While GHRP-6 itself was never commercialized as a pharmaceutical, its discovery launched an entire field of synthetic GH secretagogues and directly enabled the development of more selective GHRPs (GHRP-2, Ipamorelin, Hexarelin), orally active non-peptide GHSs (ibutamoren/MK-677), and the identification of ghrelin. In research contexts, GHRP-6 remains important not as the most potent or selective GHRP, but as the historical and pharmacological reference compound for the class — its appetite-stimulating properties are a direct experimental link between GHS-R1a signaling and feeding behavior.

Store lyophilized GHRP-6 at -20°C in a light-protected, desiccated container. The D-amino acid residues (D-Trp, D-Phe) provide resistance to enzymatic degradation. Stability exceeds 24 months under optimal storage conditions. The peptide is relatively robust — brief room-temperature exposure during reconstitution does not cause significant degradation.

After reconstitution with bacteriostatic water, GHRP-6 should be refrigerated at 2–8°C and used within 21–28 days. The reconstituted solution should be clear and colorless; any turbidity indicates aggregation and the vial should be discarded. GHRP-6 is compatible with GHRH analogs (CJC-1295 no DAC, Sermorelin) in the same syringe for combined research protocols. Do not freeze reconstituted solutions — repeated freeze-thaw cycles reduce bioactivity through peptide aggregation.